- Johnson & Johnson (NYSE: JNJ) is a leading healthcare company based in New Brunswick, New Jersey, specializing in pharmaceuticals, medical devices, and consumer health products, with a strong market position bolstered by a diverse portfolio and a focus on innovation.
- In Q1 2026, J&J reported a 9.9% year-over-year revenue increase to $24.1 billion and raised its full-year revenue guidance to $100.8 billion, driven by strategic expansions in its oncology portfolio and MedTech acquisitions, including the submission of the Ottava robotic surgical system to the FDA.
- The company has made significant strides in product approvals, including ICOTYDE for plaque psoriasis and TECVAYLI plus DARZALEX FASPRO for multiple myeloma, showcasing its commitment to addressing critical healthcare needs.
- J&J's ideal buyers include healthcare providers and institutions seeking innovative medical solutions, as the company addresses pain points related to chronic diseases and surgical efficiency, making it a key player for sales teams focused on the healthcare sector.
Johnson & Johnson's workforce is organized into 19 departments, with Operations leading at 10,838 employees, followed by Information Technology with 7,259 and the Executive department at 6,919. This distribution indicates a strong emphasis on operational efficiency and technological support, critical for a pharmaceutical company. The balance across departments reflects a comprehensive approach to business functions, ensuring robust support in sales, finance, and community services as well.
The company operates in 1,520 locations, with a significant concentration in New Brunswick, NJ, housing 4,170 employees, followed by New York, NY with 1,394 and East Brunswick, NJ with 1,252. The substantial 'Other' category, comprising 39,745 employees, suggests a widespread and distributed workforce, enhancing operational flexibility. This geographic distribution underscores Johnson & Johnson's extensive reach across various regions, facilitating local engagement and support.
